Celyad: Directing a weaponised attack on cancer with NKR-T cell-based immunotherapy




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Celyad: Directing a weaponised attack on cancer with NKR-T cell-based immunotherapy
Released on: August 15, 2017. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Celyad focuses on translating promising research into transformative treatments aimed at reversing the outcome of severe diseases.
  • Summary
  • Transcript
  • Participants
  • Company
Celyad focuses on translating promising research into transformative treatments aimed at reversing the outcome of severe diseases. Celyad identifies and further advances therapeutic solutions that have the potential to change the lives of thousands of patients worldwide. Georges Rawadi talks to Adrian Dawkes about how Celyad is using NK receptors to battle cancers.
Celyad focuses on translating promising research into transformative treatments aimed at reversing the outcome of severe diseases. Celyad identifies and further advances therapeutic solutions that have the potential to change the lives of thousands of patients worldwide. Georges Rawadi talks to Adrian Dawkes about how Celyad is using NK receptors to battle cancers.
Georges Rawad
Celyad focuses on translating promising research into transformative treatments aimed at reversing the outcome of severe diseases. Celyad identifies and further advances therapeutic solutions that have the potential to change the lives of thousands of patients worldwide. Georges Rawadi talks to Adrian Dawkes about how Celyad is using NK receptors to battle cancers.